Tern-101

Phase 2Small molecule

TTerns, Inc.

Tern-101 is one of 50 small molecule programs targeting Non-Alcoholic Steatohepatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Alcoholic SteatohepatitisActive, not recruiting

Non-Alcoholic SteatohepatitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

96 competitors in Non-Alcoholic Steatohepatitis

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Phase 3

4 2

Victoza

Novo Nordisk

Phase 3

2 3

Uloric

Takeda

Phase 2

1 4

Farxiga

AstraZeneca

Phase 2

1 5

Dipeptidyl Peptidase 4 Inhibitor

Boehringer Ingelheim

Phase 3

1 6

Metadoxine

AAlcobra Ltd.

Phase 3

1 7

Diosmin

TTanta University

Phase 3

1 8

Efruxifermin

Akero Therapeutics

Phase 3

1 9

Zetia

OOrganon and Co

Phase 2

2 10

Legalon

BBukwang Pharmaceutical

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Non-Alcoholic Steatohepatitis2 trials

DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis

Completed·TTerns, Inc.·Phase 2·NCT05415722·162 enrolled

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2a Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Orally Administered TERN-101 Tablets in Adult Patients With Presumed Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)

Completed·TTerns, Inc.·Phase 2·NCT04328077·101 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Tern-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tern-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tern-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Terns, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTerns, Inc.

Tern-101

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Non-Alcoholic Steatohepatitis2 trials

References

Drug Info

Quick Facts

Related News